Health and Healthcare
Why This Ovarian Cancer Drug Could Be Huge for NewLink Genetics
Published:
NewLink Genetics Corp. (NASDAQ: NLNK) shares jumped on Tuesday after the company announced that it entered into an exclusive worldwide license agreement with Ellipses Pharma.
The agreement is for the development of and rights to commercialize NLG207 for the treatment of ovarian cancer.
Under the terms of the agreement, Ellipses purchased NewLink’s inventory of NLG207 related materials, and NewLink will have the potential to receive future royalty payments or a share of any future economics related to NLG207.
As part of the license agreement, Ellipses also gained the rights to develop and commercialize CRLX-301, a nanoparticle formulation of docetaxel that has completed a Phase 1a study.
Dr. Rajan Jethwa, CEO and founder of Ellipses, commented:
We are excited to have reached an agreement with NewLink on a worldwide license for NLG207. Our Scientific Affairs Group confirmed that this compound has shown some encouraging signs in Phase 2 trials and has the potential to improve the standard of care for patients with ovarian cancer that recurs after initial treatment. Our dedicated clinical trials team is eager to rapidly progress the development of this compound for patients suffering from a devastating disease and who currently have relatively few treatment options.
Shares of NewLink traded up about 15% at $2.25 early Tuesday, in a 52-week range of $1.13 to $2.37. The consensus price target is $4.00.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
